MediciNova Gelecekteki Büyüme

Future kriter kontrolleri 0/6

MediciNova'in kazançlarının yıllık 6.1% oranında azalacağı tahmin edilmektedir. EPS'nin azalması yıllık 4.8% oranında azalması beklenmektedir.

Anahtar bilgiler

-6.1%

Kazanç büyüme oranı

-4.8%

EPS büyüme oranı

Biotechs kazanç büyümesi28.5%
Gelir büyüme oranın/a
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme25 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Aug 28
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Apr 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Nov 27
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Jul 11
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Mar 18
Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Oct 12
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova to get US patent for MN-166 to treat brain cancer

Sep 15

MediciNova's MN-166 to be part of study to treat Long COVID

Aug 16

MediciNova begins study of parenteral formulation of MN-166

Jul 22

MediciNova announces extension of BARDA contract for Ibudilast development

Jun 30

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Mar 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Nov 23
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

MediciNova: The Pain Of A Positive Outlook

Aug 31

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

Jun 21

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

May 15
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

The MediciNova Riddle: Worth Unravelling

Apr 26

MediciNova inks $20M securities purchase agreement with 3D Investment Partners

Jan 12

MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis

Dec 29

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Dec 29
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:MNOV - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026N/A-12N/AN/A1
12/31/2025N/A-12N/AN/A1
12/31/2024N/A-11N/AN/A1
9/30/2024N/A-10-9-9N/A
6/30/20241-8-9-9N/A
3/31/20241-8-8-8N/A
12/31/20231-9-7-7N/A
9/30/20231-10-11-11N/A
6/30/2023N/A-12-12-12N/A
3/31/2023N/A-14-12-12N/A
12/31/2022N/A-14-13-13N/A
9/30/2022N/A-13-13-13N/A
6/30/20220-13-13-13N/A
3/31/20220-13-9-9N/A
12/31/20214-10-9-9N/A
9/30/20214-11-8-8N/A
6/30/20214-11-9-9N/A
3/31/20214-11-12-12N/A
12/31/2020N/A-14-11-11N/A
9/30/2020N/A-13-11-11N/A
6/30/2020N/A-12-9-9N/A
3/31/2020N/A-11-9-9N/A
12/31/2019N/A-13-9-9N/A
9/30/2019N/A-11-8-8N/A
6/30/2019N/A-16-8-8N/A
3/31/2019N/A-15-8-8N/A
12/31/2018N/A-15-9-9N/A
9/30/2018N/A-16-9-9N/A
6/30/2018N/A-13N/A-9N/A
3/31/2018N/A-13N/A-8N/A
12/31/2017N/A-11N/A-7N/A
9/30/2017N/A-11N/A-7N/A
6/30/2017N/A-10N/A-7N/A
3/31/2017N/A-11N/A-7N/A
12/31/2016N/A-11N/A-7N/A
9/30/2016N/A-12N/A-7N/A
6/30/2016N/A-11N/A-7N/A
3/31/2016N/A-10N/A-6N/A
12/31/2015N/A-9N/A-7N/A
9/30/2015N/A-8N/A-7N/A
6/30/2015N/A-9N/A-7N/A
3/31/2015N/A-9N/A-7N/A
12/31/2014N/A-9N/A1N/A
9/30/20146-3N/A-2N/A
6/30/20146-3N/A-2N/A
3/31/20146-4N/A-3N/A
12/31/20136-4N/A-11N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MNOV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: MNOV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: MNOV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: MNOV şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: MNOV gelecek yıl gelir elde edemeyeceği tahmin ediliyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MNOV 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin